INVA

Innoviva reported strong third-quarter performance in October 2025 and the board authorized a $125 million share repurchase program. Innoviva Specialty Therapeutics received U.S. FDA approval for NUZOLVENCE in December 2025. Innoviva reported strong 2025 results in February 2026 with 15% revenue growth and IST generated 47% year-over-year U.S. sales growth. Innoviva reported a profitable first quarter of 2026 in May 2026, with total revenue of $98.0 million and net income of $186.6 million, largely investment-driven. Innoviva filed a shelf registration for a potential $208 million stock offering in May 2026, raising dilution concerns. Analysts have maintained a "Moderate Buy" consensus rating with an average price target suggesting significant upside.